NO20065084L - Interferon-alpha polypeptides and conjugates - Google Patents
Interferon-alpha polypeptides and conjugatesInfo
- Publication number
- NO20065084L NO20065084L NO20065084A NO20065084A NO20065084L NO 20065084 L NO20065084 L NO 20065084L NO 20065084 A NO20065084 A NO 20065084A NO 20065084 A NO20065084 A NO 20065084A NO 20065084 L NO20065084 L NO 20065084L
- Authority
- NO
- Norway
- Prior art keywords
- conjugates
- polypeptides
- nucleic acids
- interferon
- alpha polypeptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer interferon-alfa-polypeptider og konjugater, samt nukleinsyrer som koder for polypeptidene. Oppfinnelsen omfatter også sammensetninger omfattende disse polypeptidene, konjugatene og nukleinsyrene; celler inneholdende eller som uttrykker polypeptidene, konjugatene og nukleinsyrene; fremgangsmåter for fremstilling av polypeptidene, konjugatene og nukleinsyrene; og fremgangsmåter for anvendelse av polypeptidene, konjugatene og nukleinsyrene.The present invention provides interferon-alpha polypeptides and conjugates, as well as nucleic acids encoding the polypeptides. The invention also encompasses compositions comprising these polypeptides, conjugates and nucleic acids; cells containing or expressing the polypeptides, conjugates and nucleic acids; processes for preparing the polypeptides, conjugates and nucleic acids; and methods for using the polypeptides, conjugates, and nucleic acids.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57250404P | 2004-05-19 | 2004-05-19 | |
PCT/US2005/017471 WO2005113592A2 (en) | 2004-05-19 | 2005-05-18 | Interferon-alpha polypeptides and conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065084L true NO20065084L (en) | 2006-12-01 |
Family
ID=35428915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065084A NO20065084L (en) | 2004-05-19 | 2006-11-03 | Interferon-alpha polypeptides and conjugates |
Country Status (14)
Country | Link |
---|---|
US (9) | US7318918B2 (en) |
EP (1) | EP1753779A2 (en) |
JP (1) | JP2008507298A (en) |
CN (1) | CN101115769A (en) |
AR (1) | AR049177A1 (en) |
AU (1) | AU2005245918A1 (en) |
BR (1) | BRPI0511196A (en) |
CA (1) | CA2566247A1 (en) |
IL (1) | IL178470A0 (en) |
MX (1) | MXPA06013412A (en) |
NO (1) | NO20065084L (en) |
RU (1) | RU2006145020A (en) |
TW (1) | TW200611910A (en) |
WO (1) | WO2005113592A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60042730D1 (en) | 1999-01-05 | 2009-09-24 | Univ Boston | IMPROVED CLONING PROCESS |
US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
US7435562B2 (en) | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
US20030017552A1 (en) * | 2000-07-21 | 2003-01-23 | Jarrell Kevin A. | Modular vector systems |
KR20070038462A (en) * | 2004-05-12 | 2007-04-10 | 퓨전원 인코포레이티드 | Advanced contact identification system |
ATE540110T1 (en) | 2004-11-11 | 2012-01-15 | Modular Genetics Inc | OLIGONUCLEOTIDE LADDER CONSTRUCTION AND SYSTEM FOR GENERATING MOLECULAR DIVERSITY |
US20080124302A1 (en) * | 2005-03-09 | 2008-05-29 | Guangwen Wei | Uses of Recombinant Super-Compound Interferons |
CA2607651A1 (en) | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Evolved interferon-alpha polypeptides |
AR078117A1 (en) * | 2006-06-20 | 2011-10-19 | Protech Pharma S A | A RECOMBINANT MUTEIN OF THE GLICOSILATED HUMAN ALPHA INTERFERON, A CODIFYING GENE FOR SUCH MUTEIN, A METHOD OF PRODUCTION OF SUCH GENE, A METHOD FOR OBTAINING A EUCARIOTE CELL MANUFACTURING THIS MUTEINE, A METHOD FOR A MUTE DIFFERENT PROCEDURE |
WO2008008808A2 (en) * | 2006-07-11 | 2008-01-17 | Modular Genetics Inc. | Methods of introducing targeted diversity into nucleic acid molecules |
WO2008013082A1 (en) * | 2006-07-25 | 2008-01-31 | Galpharma Co., Ltd. | Galectin 9-polymer conjugate |
US7808342B2 (en) * | 2006-10-02 | 2010-10-05 | Skyworks Solutions, Inc. | Harmonic phase tuning filter for RF switches |
US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
WO2009006579A1 (en) * | 2007-07-05 | 2009-01-08 | Pharmaessentia Corp. | Peptide-polymer conjugates |
TWI544930B (en) * | 2007-10-01 | 2016-08-11 | 藥華醫藥股份有限公司 | N-terminal modified interferon-alpha |
CA2711375C (en) * | 2008-01-18 | 2019-04-16 | F. Hoffmann-La Roche Ag | Purification of not-glycosylated polypeptides |
US7954022B2 (en) * | 2008-01-30 | 2011-05-31 | Alcatel-Lucent Usa Inc. | Apparatus and method for controlling dynamic modification of a scan path |
CN102281903B (en) * | 2008-11-17 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
EP2391714B2 (en) | 2009-01-30 | 2019-07-24 | Whitehead Institute for Biomedical Research | Methods for ligation and uses thereof |
AR086659A1 (en) * | 2011-06-02 | 2014-01-15 | Hanmi Science Co Ltd | INSULIN-POLYMER NON-PEPTIDILE MULTIMER AND METHOD FOR PRODUCTION |
WO2013003555A1 (en) | 2011-06-28 | 2013-01-03 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
CN102358897B (en) * | 2011-10-31 | 2013-02-13 | 北京三元基因工程有限公司 | Preparation method of recombinant human oligoadenylate synthetase-1 |
EP3139955B1 (en) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusion proteins for treating cancer and related methods |
EP3006045B3 (en) * | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
KR20180098625A (en) | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | Formulation with reduced degradation of polysorbate |
RU2650755C1 (en) * | 2017-05-24 | 2018-04-17 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Method for cleaning the medicament of prolonged action on the basis of the recombinant analogue of alpha-17 interferon for viral hepatitis c treatment |
BR112022014567A2 (en) * | 2020-01-24 | 2022-09-27 | Alkermes Pharma Ireland Ltd | PURIFICATION METHODS |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
US4414150A (en) | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
ES8302778A1 (en) | 1980-11-10 | 1983-02-01 | Genentech Inc | Hybrid human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them. |
IT1167610B (en) | 1982-01-19 | 1987-05-13 | Cetus Corp | MULTICLASS HYBRID INTERFRERON, PHARMACEUTICAL COMPOSITION CONTAINING IT AND PRODUCTION PROCESS |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
JPS60152058A (en) * | 1984-01-20 | 1985-08-10 | Toshiba Corp | Semiconductor memory device |
EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
US4695626A (en) * | 1986-07-29 | 1987-09-22 | Pfizer Inc. | 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
ES2128348T3 (en) | 1990-10-17 | 1999-05-16 | Amgen Inc | OBTAINING COMPOSITIONS FOR THE TREATMENT OF ALTERATIONS OF CELL PROLIFERATION. |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5574138A (en) | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6007805A (en) | 1994-03-07 | 1999-12-28 | Imperial College Of Science And Technology | Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
EP1012184B1 (en) | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
BR122013003013B8 (en) | 1999-01-14 | 2021-07-06 | Bolder Biotechnology Inc | Monopegylated growth hormone isolated protein and method for obtaining it |
WO2000052153A2 (en) * | 1999-03-02 | 2000-09-08 | Maxygen, Inc. | Method to identify ligands for orphan receptors |
BR0010725A (en) | 1999-05-19 | 2002-02-19 | Lexigen Pharm Corp | Expression and export of interferon-alpha proteins as fc fusion proteins |
US20040002474A1 (en) | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
CN1451045A (en) * | 1999-10-07 | 2003-10-22 | 马克西根公司 | IFN-alpha homologues |
SK8292002A3 (en) * | 1999-11-12 | 2002-12-03 | Maxygen Holdings Ltd | A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof |
IL152804A0 (en) | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
AU2002223350A1 (en) | 2000-12-01 | 2002-06-11 | Eleanor N. Fish | Cytokine receptor binding peptides |
KR100459105B1 (en) | 2001-02-15 | 2004-12-03 | 선바이오(주) | Modified interferon-alpha 2a and 2b, and conjugate with peg derivatives thereof |
CA2503594C (en) | 2002-11-15 | 2011-05-10 | Doris Brugger | Positional isomers of peg ifn alpha 2a |
WO2004046365A2 (en) | 2002-11-18 | 2004-06-03 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
-
2005
- 2005-05-18 MX MXPA06013412A patent/MXPA06013412A/en unknown
- 2005-05-18 CN CNA2005800241473A patent/CN101115769A/en active Pending
- 2005-05-18 WO PCT/US2005/017471 patent/WO2005113592A2/en active Application Filing
- 2005-05-18 EP EP05751765A patent/EP1753779A2/en not_active Withdrawn
- 2005-05-18 CA CA002566247A patent/CA2566247A1/en not_active Abandoned
- 2005-05-18 RU RU2006145020/04A patent/RU2006145020A/en unknown
- 2005-05-18 US US11/132,722 patent/US7318918B2/en not_active Expired - Fee Related
- 2005-05-18 BR BRPI0511196-0A patent/BRPI0511196A/en not_active Application Discontinuation
- 2005-05-18 JP JP2007527427A patent/JP2008507298A/en active Pending
- 2005-05-18 TW TW094116107A patent/TW200611910A/en unknown
- 2005-05-18 AU AU2005245918A patent/AU2005245918A1/en not_active Abandoned
- 2005-05-19 AR ARP050102059A patent/AR049177A1/en unknown
-
2006
- 2006-09-13 US US11/531,531 patent/US7531630B2/en not_active Expired - Fee Related
- 2006-09-13 US US11/531,570 patent/US20070020734A1/en not_active Abandoned
- 2006-09-13 US US11/531,557 patent/US7531324B2/en not_active Expired - Fee Related
- 2006-09-14 US US11/532,045 patent/US20070225205A1/en not_active Abandoned
- 2006-09-14 US US11/532,024 patent/US20070225204A1/en not_active Abandoned
- 2006-10-05 IL IL178470A patent/IL178470A0/en unknown
- 2006-11-03 NO NO20065084A patent/NO20065084L/en unknown
-
2007
- 2007-05-04 US US11/744,424 patent/US7541436B2/en not_active Expired - Fee Related
- 2007-08-14 US US11/838,730 patent/US7541163B2/en not_active Expired - Fee Related
- 2007-08-15 US US11/839,493 patent/US7537755B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20070225205A1 (en) | 2007-09-27 |
US20070225204A1 (en) | 2007-09-27 |
AR049177A1 (en) | 2006-07-05 |
WO2005113592A3 (en) | 2006-04-06 |
US7318918B2 (en) | 2008-01-15 |
CN101115769A (en) | 2008-01-30 |
US20080076710A1 (en) | 2008-03-27 |
TW200611910A (en) | 2006-04-16 |
US20080171363A1 (en) | 2008-07-17 |
AU2005245918A1 (en) | 2005-12-01 |
RU2006145020A (en) | 2008-06-27 |
US7541436B2 (en) | 2009-06-02 |
US7537755B2 (en) | 2009-05-26 |
US20050266465A1 (en) | 2005-12-01 |
BRPI0511196A (en) | 2007-12-04 |
US20070020235A1 (en) | 2007-01-25 |
IL178470A0 (en) | 2007-02-11 |
US20070020734A1 (en) | 2007-01-25 |
US20070025966A1 (en) | 2007-02-01 |
JP2008507298A (en) | 2008-03-13 |
EP1753779A2 (en) | 2007-02-21 |
CA2566247A1 (en) | 2005-12-01 |
US7531630B2 (en) | 2009-05-12 |
US7541163B2 (en) | 2009-06-02 |
WO2005113592A2 (en) | 2005-12-01 |
MXPA06013412A (en) | 2007-01-23 |
US7531324B2 (en) | 2009-05-12 |
US20080031853A1 (en) | 2008-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065084L (en) | Interferon-alpha polypeptides and conjugates | |
NO20052363L (en) | Interferon-alpha polypeptides and conjugates | |
WO2006083276A3 (en) | Interferon-alpha polypeptides and conjugates | |
WO2004029219A3 (en) | Cell-based rna interference and related methods and compositions | |
WO2005121331A8 (en) | Truncated galnact2 polypeptides and nucleic acids | |
HK1210627A1 (en) | Preparing crude biological estracts using protease, suitable for preparing cdna cdna | |
WO2003104418A3 (en) | Reconstituted polypeptides | |
DK1409459T3 (en) | ECL labels which have improved, non-specific binding properties, methods of using them, and kits containing the same. | |
NO20090047L (en) | Anti-DLL4 antibodies and methods for their use | |
WO2006017538A3 (en) | Hk1-binding proteins | |
DK1641910T3 (en) | Glucanases, nucleic acids encoding them, and methods of preparing and utilizing them | |
DK1516053T3 (en) | Xylanases, their coding nucleic acids, and processes for their preparation and use | |
WO2006066024A8 (en) | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same | |
DK1131444T3 (en) | Polypeptides with lysophospholipase activity and nucleic acid encoding them | |
RS50660B (en) | Dihydrotetrabenazines and pharmaceutical compositions containing them | |
NO20062709L (en) | Stem cells suitable for transplantation, preparation thereof and pharmaceutical preparations comprising said stem cells | |
WO2008121324A3 (en) | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells | |
WO2005087793A3 (en) | Immunostimulatory compositions and uses thereof | |
WO2004061080A3 (en) | Stress-related polypeptides and uses therefor | |
NO20072966L (en) | Polypeptides having antimicrobial activity and polynucleotides encoding them | |
WO2005103229A3 (en) | Transgenomic mitochondria, transmitochondrial cells and organisms, and methods of making and using | |
WO2004007664A3 (en) | Nucleic acid vectors | |
WO2006039396A3 (en) | Non-embedded tissue microarray technology for protein and nucleic acid analyses | |
WO2006063028A3 (en) | Immunostimulatory compositions and uses thereof | |
WO2001049721A3 (en) | Bacterial genes and proteins that are essential for cell viability and their uses |